Piribedil is a non-ergot D2/D3 dopamine agonist with antagonistic effect on α2-adrenoceptors
and lack of agonist properties at 5-HT2A/2C receptors. Previous studies indicated its efficacy in monotherapy
as well as in combination with L-dopa in treating Parkinson’s disease patients.